317 related articles for article (PubMed ID: 37154101)
21. Resistance to DNA repair inhibitors in cancer.
Baxter JS; Zatreanu D; Pettitt SJ; Lord CJ
Mol Oncol; 2022 Nov; 16(21):3811-3827. PubMed ID: 35567571
[TBL] [Abstract][Full Text] [Related]
22. Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells.
Carruthers RD; Ahmed SU; Ramachandran S; Strathdee K; Kurian KM; Hedley A; Gomez-Roman N; Kalna G; Neilson M; Gilmour L; Stevenson KH; Hammond EM; Chalmers AJ
Cancer Res; 2018 Sep; 78(17):5060-5071. PubMed ID: 29976574
[TBL] [Abstract][Full Text] [Related]
23. Implications of DNA damage repair alterations for the management of prostate cancer.
Lozano R; Olmos D; Castro E
Curr Opin Urol; 2022 May; 32(3):302-310. PubMed ID: 35266912
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
[TBL] [Abstract][Full Text] [Related]
25. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
26. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
[TBL] [Abstract][Full Text] [Related]
27. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications.
Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E
Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534
[TBL] [Abstract][Full Text] [Related]
28. Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
Beltzig L; Christmann M; Kaina B
Cells; 2022 Aug; 11(16):. PubMed ID: 36010664
[TBL] [Abstract][Full Text] [Related]
29.
Rafiei S; Fitzpatrick K; Liu D; Cai MY; Elmarakeby HA; Park J; Ricker C; Kochupurakkal BS; Choudhury AD; Hahn WC; Balk SP; Hwang JH; Van Allen EM; Mouw KW
Cancer Res; 2020 Jun; 80(11):2094-2100. PubMed ID: 32127357
[TBL] [Abstract][Full Text] [Related]
30. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
31. Combination DNA Damage Response (DDR) Inhibitors to Overcome Drug Resistance in Ovarian Cancer.
Nasioudis D; George EM; Xu H; Kim H; Simpkins F
Cancer Treat Res; 2023; 186():189-206. PubMed ID: 37978137
[TBL] [Abstract][Full Text] [Related]
32. DNA damage response pathways in tumor suppression and cancer treatment.
Liang Y; Lin SY; Brunicardi FC; Goss J; Li K
World J Surg; 2009 Apr; 33(4):661-6. PubMed ID: 19034564
[TBL] [Abstract][Full Text] [Related]
33. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
34. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
35. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Sabbatino F; Fusciello C; Somma D; Pacelli R; Poudel R; Pepin D; Leonardi A; Carlomagno C; Della Vittoria Scarpati G; Ferrone S; Pepe S
Cytometry A; 2014 Nov; 85(11):953-61. PubMed ID: 25182801
[TBL] [Abstract][Full Text] [Related]
36. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Aktas BY; Guner G; Guven DC; Arslan C; Dizdar O
Expert Rev Anticancer Ther; 2019 Jul; 19(7):589-601. PubMed ID: 31181965
[No Abstract] [Full Text] [Related]
37. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
38. Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms.
Garzón-Hernández C; Ramírez-Merino N; Soberon MCM
Arch Med Res; 2022 Dec; 53(8):807-817. PubMed ID: 36460545
[TBL] [Abstract][Full Text] [Related]
39. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
[TBL] [Abstract][Full Text] [Related]
40. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
